Chemokine Announces Patent Issuance for Chemokine Analogs
Complete the form below to unlock access to ALL audio articles.
Chemokine Therapeutics Corp. has announced that the United States Patent and Trademark Office has issued U.S. Patent 7,091,310 B2 relating to chemokine analogs for the treatment of human disease.
The patent covers chemokine analogs (peptide agonists and antagonists of chemokines) that are useful for the treatment of a variety of diseases and disorders, and as an adjunct to the treatment of a variety of diseases and disorders, including autoimmune diseases, acute chronic inflammation, cancer, cardiovascular disease, infectious disease and inflammatory disorders such as rheumatoid arthritis, chronic inflammatory bowel disease, chronic inflammatory pelvic disease, multiple sclerosis, asthma, osteoarthritis, atherosclerosis, psoriasis, rhinitis, autoimmunity and organ transplant rejection.
Dr. Hassan Salari, President and Chief Executive Officer of Chemokine Therapeutics, stated, "This new patent grant reinforces our overriding strategy to broaden the proprietary scope of our drug development platform while helping to further solidify our intellectual property position."
